Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens

Vaccine

Volumn 27, Issue 24, 2009, Pages 3165-3174

  Gómez, Carmen E ^a   Nájera, José L ^a   Sánchez, Raquel ^a   Jiménez, Victoria ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

HIV; MegaCD40L; Mouse model; MVA B; NYVAC B; Poxvirus; Vaccine

Indexed keywords

CD40 LIGAND; DNA; ENVELOPE PROTEIN; GAG PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEF PROTEIN; POL PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; EMBRYO; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; INOCULATION; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; POLARIZATION; POXVIRUS; PRIORITY JOURNAL; TH1 CELL; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENETIC VECTORS; HIV ANTIGENS; HIV-1; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; POXVIRIDAE; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 67349168133     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.049     Document Type: Article

References (55)

1. Gomez C.E., Najera J.L., Jimenez E.P., Jimenez V., Wagner R., Graf M., et al. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1 (IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25 15 (2007) 2863-2885
2. Gomez C.E., Najera J.L., Jimenez V., Bieler K., Wild J., Kostic L., et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25 11 (2007) 1969-1992
3. + T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 82 6 (2008) 2975-2988
4. Robinson H.L., Sharma S., Zhao J., Kannanganat S., Lai L., Chennareddi L., et al. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T-cells. AIDS Res Hum Retroviruses 23 12 (2007) 1555-1562
5. Harari A., Bart P.A., Stohr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T-cell responses. J Exp Med 205 1 (2008) 63-77
6. Gomez C.E., Najera J.L., Krupa M., and Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8 2 (2008) 97-120
7. Kornbluth R.S. An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res 11 5 (2002) 787-801
8. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?. Nat Rev Immunol 3 8 (2003) 609-620
9. Watts T.H. TNF/TNFR family members in costimulation of T-cell responses. Annu Rev Immunol 23 (2005) 23-68
10. Bodmer J.L., Schneider P., and Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 27 1 (2002) 19-26
11. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 4 (2001) 487-501
12. Moodycliffe A.M., Shreedhar V., Ullrich S.E., Walterscheid J., Bucana C., Kripke M.L., et al. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes. J Exp Med 191 11 (2000) 2011-2020
13. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22 (2004) 307-328
14. Hodgkin P.D., Yamashita L.C., Seymour B., Coffman R.L., and Kehry M.R. Membranes from both Th1 and Th2 T-cell clones stimulate B cell proliferation and prepare B cells for lymphokine-induced differentiation to secrete Ig. J Immunol 147 11 (1991) 3696-3702
15. Grewal I.S., Xu J., and Flavell R.A. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 378 6557 (1995) 617-620
16. DeKruyff R.H., Gieni R.S., and Umetsu D.T. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J Immunol 158 1 (1997) 359-366
17. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184 2 (1996) 741-746
18. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 2 (1996) 747-752
19. + CTL response. J Exp Med 183 5 (1996) 2129-2142
20. Shinde S., Wu Y., Guo Y., Niu Q., Xu J., Grewal I.S., et al. CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. J Immunol 157 7 (1996) 2764-2768
21. Yang Y., and Wilson J.M. CD40 ligand-dependent T-cell activation: requirement of B7-CD28 signaling through CD40. Science 273 5283 (1996) 1862-1864
22. Jodo S., Xiao S., Hohlbaum A., Strehlow D., Marshak-Rothstein A., and Ju S.T. Apoptosis-inducing membrane vesicles. A novel agent with unique properties. J Biol Chem 276 43 (2001) 39938-39944
23. von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99 9 (2002) 3319-3325
24. Storni T., Lechner F., Erdmann I., Bachi T., Jegerlehner A., Dumrese T., et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T-cell responses after vaccination with virus-like particles. J Immunol 168 6 (2002) 2880-2886
25. Ruby J., Bluethmann H., Aguet M., and Ramshaw I.A. CD40 ligand has potent antiviral activity. Nat Med 1 5 (1995) 437-441
26. + T-cell responses. Hum Gene Ther 16 3 (2005) 348-360
27. + T-cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 26 32 (2008) 4062-4072
28. Stone G.W., Barzee S., Snarsky V., Kee K., Spina C.A., Yu X.F., et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 80 4 (2006) 1762-1772
29. Fanslow W.C., Srinivasan S., Paxton R., Gibson M.G., Spriggs M.K., and Armitage R.J. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 6 5 (1994) 267-278
30. Miconnet I., and Pantaleo G. A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T-cell response. Vaccine 26 32 (2008) 4006-4014
31. Mendoza R.B., Cantwell M.J., and Kipps T.J. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. J Immunol 159 12 (1997) 5777-5781
32. Gurunathan S., Irvine K.R., Wu C.Y., Cohen J.I., Thomas E., Prussin C., et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol 161 9 (1998) 4563-4571
33. Stone G.W., Barzee S., Snarsky V., Spina C.A., Lifson J.D., Pillai V.K., et al. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 13 11 (2006) 1223-1230
34. Manoj S., Griebel P.J., Babiuk L.A., and van Drunen Littel-van den Hurk S. Targeting with bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep. J Immunol 170 2 (2003) 989-996
35. Gares S.L., Fischer K.P., Congly S.E., Lacoste S., Addison W.R., Tyrrell D.L., et al. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol 13 8 (2006) 958-965
36. Ramirez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74 2 (2000) 923-933
37. + T-cells using an ELISPOT assay. J Immunol Methods 181 1 (1995) 45-54
38. Amara R.R., Villinger F., Staprans S.I., Altman J.D., Montefiori D.C., Kozyr N.L., et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 76 15 (2002) 7625-7631
39. Robinson H.L. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 82 6 (2007) 686-693
40. Bart P.A., Goodall R., Barber T., Harari A., Guimaraes-Walker A., Khonkarly M., et al. EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26 25 (2008) 3153-3161
41. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 198 10 (2008) 1482-1490
42. Gomez C.E., Najera J.L., Domingo-Gil E., Ochoa-Callejero L., Gonzalez-Aseguinolaza G., and Esteban M. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 88 Pt 9 (2007) 2473-2478
43. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3 3 (2003) 263-271
44. Gherardi M.M., and Esteban M. Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86 Pt 11 (2005) 2925-2936
45. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 6684 (1998) 478-480
46. + T-helper and a T-killer cell. Nature 393 6684 (1998) 474-478
47. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 393 6684 (1998) 480-483
48. Smith C.M., Wilson N.S., Waithman J., Villadangos J.A., Carbone F.R., Heath W.R., et al. Cognate CD4(+) T-cell licensing of dendritic cells in CD8(+) T-cell immunity. Nat Immunol 5 11 (2004) 1143-1148
49. + memory T-cell subsets. Proc Natl Acad Sci USA 101 15 (2004) 5610-5615
50. + T-cells: when, where, and how. Annu Rev Immunol 24 (2006) 519-540
51. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 2 (2005) 633-639
52. Estcourt M.J., McMichael A.J., and Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199 (2004) 144-155
53. Giri M., Ugen K.E., and Weiner D.B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 17 2 (2004) 370-389
54. Gurunathan S., Klinman D.M., and Seder R.A. DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol 18 (2000) 927-974
55. Robinson H.L., Montefiori D.C., Johnson R.P., Kalish M.L., Lydy S.L., and McClure H.M. DNA priming and recombinant pox virus boosters for an AIDS vaccine. Dev Biol (Basel) 104 (2000) 93-100